RecruitingNCT06446271

Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)

Biomarkers in SCOTland CardiomyopatHy Registry


Sponsor

NHS Greater Glasgow and Clyde

Enrollment

750 participants

Start Date

Jun 26, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Genetic cardiomyopathy is increasingly recognised and can lead to heart failure, arrhythmia and sudden cardiac death. Some gene positive patients have rapidly progressive disease with high rates of heart failure and cardiac transplantation, while others present with SCD. Other gene positive patients will never develop cardiomyopathy. At present, we cannot distinguish between these groups and rely on expensive and labour-intensive surveillance by electrocardiography, echocardiography and sometimes cardiac magnetic resonance imaging. This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.


Eligibility

Min Age: 10 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Plasma biomarker levels for people with cardiomyopathies, cardiomyopathy, primary, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTPlasma biomarker levels

This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy. Cardiomyopathy will be defined per European Society of Cardiology cardiomyopathy guidelines and heart failure stage will be defined per American Heart Associate guidelines.


Locations(1)

Queen Elizabeth University Hospital

Glasgow, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06446271


Related Trials